A latanoprost cationic emulsion (STN1013001) vs. other latanoprost formulations (Latanoprost) in open angle glaucoma/ocular hypertension and ocular surface disease: an Italian cost-utility analysis.

Carlo Lazzaro,Cécile van Steen, Giorgio Ghirelli,Matteo Sacchi, Dario Sisto,Maurizio Uva,Luigi Varano,Luigi Angelillo

Expert review of pharmacoeconomics & outcomes research（2023）

引用 1|浏览2

暂无评分

摘要

STN1013001 is potentially highly cost-effective and strongly dominant vs. Latanoprost for OAG/OHT+OSD patients from the INHS perspective. These findings should be re-assessed using the data from the ongoing Phase III trial (NCT04133311) comparing the efficacy and safety of STN1013001 vs. Latanoprost and with future real-world CUAs upon the availability of STN1013001 on the Italian market.

查看译文

关键词

Italy,Open-angle glaucoma,STN1013001,cost-utility analysis,early Markov model,latanoprost,ocular hypertension,ocular surface disease,value of information analysis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要